
USFDA17 Nov 2026, 02:03 pm
Caplin Point Subsidiary Facility Classified OAI by US FDA
AI Summary
Caplin Point Laboratories Ltd announced that its subsidiary, Caplin Steriles Limited, has received an "Official Action Indicated" (OAI) classification from the US FDA for its injectable and ophthalmic manufacturing facility in Gummidipoondi. The inspection, conducted between August 13-21, 2026, resulted in 10 procedural observations. The company stated that it does not anticipate any material impact on its financials or operations as of the filing date. The facility will continue to operate and supply products. Caplin Point is committed to addressing the FDA's observations and ensuring compliance with cGMP standards. Further updates will be provided if significant information becomes available.
Key Highlights
- US FDA classified Caplin Steriles' facility as OAI.
- Inspection yielded 10 procedural observations.
- No material financial or operational impact expected.
- Facility continues manufacturing and supply operations.
- Company committed to addressing FDA observations.
Price Impact
More from CAPLIPOINT